Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2141)	1/15/2008 1:53:25 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

MBRK Is up for 2nd day on a roll with no news that I am aware. bigcharts.marketwatch.com MBRK is the previous AVNC that changed its name from Advancis to MiddleBrooK.<g> It is focused on development of antibiotics,based on its finding that bacteria exposed to bursts, or "pulses," are killed more efficiently.It has developed a once-a-day pulsatile delivery technology called PULSYSTM. The stock is trying to get off from the DT coming from its Oct base at the $2.60 level.<g> bigcharts.marketwatch.com The insiders reportedly hold > 40%. The short ratio came down in the last month, & is around 2.5x its ADV. bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2141)	1/17/2008 2:12:52 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

I am not aware,so far, that there has been any effect on the SC companies from the announcement from Somagen that they got 5 human embryos using skin cells from 2 men who work at the IVF center. They said they had painstakingly verified that the embryos were clones of the two men.<g> Somagen is the former Immucor Canada Inc., founded in 1988 & focused on its early days on supplying the Canadian Blood Bank market, but in 1995 it began expanding into other laboratory markets & acquired NCS Diagnostics. They used a technique called somatic cell nuclear transfer, or SCNT, which involves hollowing out an egg cell and injecting the nucleus of a cell from the donor to be copied, in this case, the skin cells from the 2 men.That is the same technique used to make Dolly the sheep in 1996. Researchers hope to use the technique to create tailor-made transplants of cells, tissue or organs for patients, treating injuries and diseases like juvenile diabetes. They think that since a significant percentage of couples undergoing fertility treatments seem to be willing to participate, they believe the method using donated oocytes is a viable and ethically acceptable strategy. So far,it is the most successful use of the cloning techniques with purely human material, but may still be a long way from achieving the goal of obtaining embryonic stem cells. The field remains controversial.President Bush opposes the use of human embryos to make SCs & has vetoed bills that would expand federal funding of this research. South Korean scientist Hwang Woo-suk made headlines when he was found to have faked key parts of a report that his team had used cloning technology to make human embryos in 2004. Dr. Robert Lanza, of Advanced Cell Technology in Massachusetts, said that he thinks that we need to be ultra-cautious after the Hwang scandal in order to not make the same mistake again.(His company is also working on the same subject.<g>) GERN is holding at the $5 level bigcharts.marketwatch.com While STEM has continued to slide down bigcharts.marketwatch.com And ASTM is having some extra profit taking after its recent minispike <g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2141)	2/11/2008 12:35:22 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ASTM is still trying to get off the DT coming frpm its Oct 4 H at $1.43 It is up 6.92% on volume of 195,690 about 1/6 of its ADV. bigcharts.marketwatch.com On Friday it reported results for the 2ndQ & some "clinical achievements",including: The 1st cardiac patient treated with its autologous stem cell therapy for dilated cardiomyopathy. The first human application of its CRC product to regenerate damaged heart tissue. Promising interim results from the first 13 patients treated in a PI/II in Germany to evaluate the safety of VRCs, in the treatment of chronic diabetic foot wounds associated with schemia.(12 months post-treatment, all patients who were treated with VRCs reported no major amputations,no cell-related adverse events and healing of all open wounds.) Results from the 1st use of BRCs to treat 4 patients with osteonecrosis of the femoral head in Germany.(All patients tolerated the procedure well & have reported reduction in hip pain with no signs of disease progression, & were back to work within 6 months after treatment.) Results of the PI/II in the US to collect safety & efficacy data using BRCs to treat severe non-union fractures.(Of 36 patients treated,33 completed the 12months follow-up & an overall 91% healing rate was observed.) But in spite of the encouraging progress in their clinical development programs, revenues for the Q were down 50% vs. 2007 results.($84,000 vs. $158,000 in 2007.) Expenses for the Q increased to $5.621M vs. $4.898M in 2007.The loss for the Q was $5.172M ($.04/shr) vs. $4.225M ($.04/shr) in 2007. At the end of the Q,it had $31.2M in cash,vs. $28.3M at the end of the fiscal Yr. in Jun 2007.It expects a burn rate about $1.8M/month in 2008. The stock needs to close above the resistance at the $0.75 level before it can test the more important looking at $0.85 <g> The "analysts" have a consensus target for ASTM around $1.75 & it seems that with some good reports & a better market environment it could get to the $2 level.<g> bigcharts.marketwatch.com Bernard